The Baloch Liberation Army (BLA) has claimed responsibility for a series of coordinated attacks across 39 locations in ...

BLA has claimed responsibility for coordinated attacks at 39 locations across Balochistan in a bid to advance their demand ...

Discover Ocugen's Q1 2025 earnings insights, focusing on gene therapy advancements, key clinical trials, and financial updates.

Ocugen has scheduled a conference call and webcast for 8:30 a.m. ET today to discuss the financial results and recent business highlights. Ocugen’s senior management team will host the call, which ...

In the third quarter of 2025, the Company expects to present data from its ongoing Phase I/II studies of AMT-130 in support of a potential BLA submission. The update will include follow-up data on all ...

After more than a month of speculation over how the FDA will rule on Novavax’s application for an updated formulation of its ...

Axogen, Inc. ( NASDAQ: AXGN) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Michael Dale - Chairman & Chief Executive Officer Nir Naor - Chief Financial Officer Jens Kemp - Chief Marketing ...

The attack comes just days after the separatist Baloch Liberation Army (BLA) launched a violent ambush on a prison van in ...

At least 14 Pakistani army personnel were killed in two separate attacks carried out by the Baloch Liberation Army (BLA) in ...

A "productive" meeting with the FDA has given the firm confidence in its regulatory filing and commercialization plans for ST-920.

The resubmitted biologics license application for narsoplimab in transplant-associated thrombotic microangiopathy has been ...

The FDA granted Priority Review to lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP). Lenacapavir is a long-acting HIV-1 capsid inhibitor administered as a twice-yearly ...